Description
WHAT IT IS
A liquid serum formulated by Dr Yannis Alexandrides to smooth, hydrate and reduce blemishes.
WHAT IT DOES
The Anti Blemish Booster Serum targets and prevents blemishes, inflammation and post blemish pigmentation without drying the skin. Suitable for blemish-prone skin, the booster helps to clear skin using Salicylic Acid and Willow Bark Extract, a gentle exfoliant that clears clogged pores and prevent future breakouts.
KEY BENEFITS
Gently exfoliates and cleans pores to prevent future breakouts
Targets redness and blemish discoloration
KEY INGREDIENTS
Salicylic Acid: gently exfoliates, unclogs pores, prevents breakouts
Willow Bark Extract: natural exfoliant that promotes smoother, calmer skin. Minimizes the appearance of pores through its anti-inflammatory properties
Niacinamide: Brightens & evens skin tone. Rebalances pigmentation and strengthens the skin barrier.
Hyaluronic Acid: deeply hydrates and nourishes the skin
HOW TO USE
1. Shake well before use
2. Apply three to five drops, distributing evenly between fingertips
3. Gently pat all over face, neck and dcolletage
4. Use alone, mixed with serum or moisturizer, or apply directly to blemishes for a targeted treatment
5. Follow with 111SKIN Day or Night Cream
ABOUT THE BRAND
Developed by world-renowned Plastic and Reconstructive Surgeon Dr Yannis Alexandrides, 111SKIN distils the transformative results of plastic surgery into luxurious over-the-counter formulas that are non-irritating and suitable for daily use. Driven by 30+ years of medical experience, the products are powered by next-generation actives, including the innovative NAC Y2TM complex a first-of-its-kind ingredient, engineered by Dr Yannis for his Harley Street clients, that helps optimise and accelerate skin repair post-surgery, and restore skin health and slowing ageing process.
CARE
Avoid direct contact with eyes, if product gets into eyes rinse well with water immediately. Do not store in direct sunlight. In case of any irritation, discontinue use.
Reviews
There are no reviews yet.